These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 1471420)

  • 1. Availability of quality vaccines: the industrial point of view.
    Vandersmissen W
    Vaccine; 1992; 10(13):955-7. PubMed ID: 1471420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The global capacity for manufacturing vaccines. Prospects for competition and collaboration among producers in the next decade.
    Robbins A; Arita I
    Int J Technol Assess Health Care; 1994; 10(1):39-46. PubMed ID: 8157459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Availability of quality vaccines: policies of a non-government organization.
    Poore P
    Vaccine; 1992; 10(13):958-60. PubMed ID: 1471421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developing Countries Vaccine Manufacturers Network: doing good by making high-quality vaccines affordable for all.
    Pagliusi S; Leite LC; Datla M; Makhoana M; Gao Y; Suhardono M; Jadhav S; Harshavardhan GV; Homma A
    Vaccine; 2013 Apr; 31 Suppl 2():B176-83. PubMed ID: 23598479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Children's Vaccine Initiative and vaccine supply: the role of the public sector.
    van Noort RB
    Vaccine; 1992; 10(13):909-10. PubMed ID: 1471410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developing Countries Vaccine Manufacturers Network (DCVMN): engaging to step up for vaccine discovery and access. Meeting report 2012.
    Pagliusi S; Makhoana M; Datla M; Leite L; Hendriks J; Gholami A; Huang W; Gao Y; Jadhav S; Harshavardhan GV; Wu Y; Suhardono M; Homma A
    Vaccine; 2013 Jun; 31(31):3111-5. PubMed ID: 23684836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The countries' point of view.
    Schatzmayr HG
    Vaccine; 1992; 10(13):954. PubMed ID: 1471419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries.
    Jadhav S; Datla M; Kreeftenberg H; Hendriks J
    Vaccine; 2008 Mar; 26(13):1611-5. PubMed ID: 18294742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The global vaccine enterprise: a developing world perspective.
    Shin SI
    Nat Med; 1998 May; 4(5 Suppl):503-5. PubMed ID: 9585198
    [No Abstract]   [Full Text] [Related]  

  • 10. Availability of vaccines of an assured quality.
    Magrath DI
    Vaccine; 1992; 10(13):952-3. PubMed ID: 1471418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Vaccines: producers in countries of the Southern hemisphere].
    Bertrand JJ
    Med Trop (Mars); 2007 Aug; 67(4):347-50. PubMed ID: 17926792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine production, distribution, access, and uptake.
    Smith J; Lipsitch M; Almond JW
    Lancet; 2011 Jul; 378(9789):428-38. PubMed ID: 21664680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of emerging manufacturers in access to innovative vaccines of public health importance.
    Milstien JB; Kaddar M
    Vaccine; 2010 Feb; 28(9):2115-21. PubMed ID: 20044054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Better vaccines for healthier life. Part II. Conference report of the DCVMN International 14th Annual General Meeting Hanoi, Vietnam.
    Pagliusi S; Tippoo P; Sivaramakrishnan V; Nguyen T;
    Vaccine; 2014 Nov; 32(48):6330-5. PubMed ID: 24923638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WHO expectation and industry goals.
    Vandersmissen W
    Vaccine; 2001 Feb; 19(13-14):1611-5. PubMed ID: 11166883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laboratories which produce veterinary vaccines.
    Randall DC
    Rev Sci Tech; 1998 Aug; 17(2):568-77. PubMed ID: 9713896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. United States of America Department of Health and Human Services support for advancing influenza vaccine manufacturing in the developing world.
    Perdue ML; Bright RA
    Vaccine; 2011 Jul; 29 Suppl 1():A48-50. PubMed ID: 21684430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Towards a new vaccine economy?].
    Poirot P; Martin JF
    Sante; 1994; 4(3):183-7. PubMed ID: 7921683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Improving global access to new vaccines: intellectual property, technology transfer, and regulatory pathways].
    Crager SE
    Rev Panam Salud Publica; 2015 Jan; 37(1):59-68. PubMed ID: 25791189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managing the effect of TRIPS on availability of priority vaccines.
    Milstien J; Kaddar M
    Bull World Health Organ; 2006 May; 84(5):360-5. PubMed ID: 16710544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.